Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
P/E ratio for Biofrontera Inc. (BFRI)
P/E ratio as of 2023: -0.21
According to Biofrontera Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.21. At the end of 2022 the company had a P/E ratio of -30.29.
P/E ratio history for Biofrontera Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.21 |
| 2022 | -30.29 |
| 2021 | -3.41 |
| 2020 | -4.66 |
| 2019 | -4.88 |